Abstract
For more than 30 years the filoviruses, Marburg virus and Ebola virus, have been associated with periodic outbreaks of hemorrhagic fever that produce severe and often fatal disease. The filoviruses are endemic primarily in resource-poor regions in Central Africa and are also potential agents of bioterrorism. Although no vaccines or antiviral drugs for Marburg or Ebola are currently available, remarkable progress has been made over the last decade in developing candidate preventive vaccines against filoviruses in nonhuman primate models. Due to the generally remote locations of filovirus outbreaks, a single-injection vaccine is desirable. Among the prospective vaccines that have shown efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant VSV (rVSV), were shown to provide complete protection to nonhuman primates when administered as a single injection. The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 344-357 |
| Number of pages | 14 |
| Journal | Reviews in Medical Virology |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2010 |
Fingerprint
ASJC Scopus subject areas
- Virology
- Infectious Diseases
Cite this
Prospects for immunisation against Marburg and Ebola viruses. / Geisbert, Thomas; Bausch, Daniel G.; Feldmann, Heinz.
In: Reviews in Medical Virology, Vol. 20, No. 6, 11.2010, p. 344-357.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prospects for immunisation against Marburg and Ebola viruses
AU - Geisbert, Thomas
AU - Bausch, Daniel G.
AU - Feldmann, Heinz
PY - 2010/11
Y1 - 2010/11
N2 - For more than 30 years the filoviruses, Marburg virus and Ebola virus, have been associated with periodic outbreaks of hemorrhagic fever that produce severe and often fatal disease. The filoviruses are endemic primarily in resource-poor regions in Central Africa and are also potential agents of bioterrorism. Although no vaccines or antiviral drugs for Marburg or Ebola are currently available, remarkable progress has been made over the last decade in developing candidate preventive vaccines against filoviruses in nonhuman primate models. Due to the generally remote locations of filovirus outbreaks, a single-injection vaccine is desirable. Among the prospective vaccines that have shown efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant VSV (rVSV), were shown to provide complete protection to nonhuman primates when administered as a single injection. The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure.
AB - For more than 30 years the filoviruses, Marburg virus and Ebola virus, have been associated with periodic outbreaks of hemorrhagic fever that produce severe and often fatal disease. The filoviruses are endemic primarily in resource-poor regions in Central Africa and are also potential agents of bioterrorism. Although no vaccines or antiviral drugs for Marburg or Ebola are currently available, remarkable progress has been made over the last decade in developing candidate preventive vaccines against filoviruses in nonhuman primate models. Due to the generally remote locations of filovirus outbreaks, a single-injection vaccine is desirable. Among the prospective vaccines that have shown efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant VSV (rVSV), were shown to provide complete protection to nonhuman primates when administered as a single injection. The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure.
UR - http://www.scopus.com/inward/record.url?scp=77958597255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958597255&partnerID=8YFLogxK
U2 - 10.1002/rmv.661
DO - 10.1002/rmv.661
M3 - Article
C2 - 20658513
AN - SCOPUS:77958597255
VL - 20
SP - 344
EP - 357
JO - Reviews in Medical Virology
JF - Reviews in Medical Virology
SN - 1052-9276
IS - 6
ER -